InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2021-10-01 00:00:00 ET · period of report 2021-09-30 · accession 0001654954-21-010720 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-10-01 2021-09-30 MNPR Mazar Andrew Paul CSO, Dir F - Tax $4.87 -471 18.7K -2% -$2,294
D 2021-10-01 2021-09-30 MNPR Mazar Andrew Paul CSO, Dir M - OptEx — +1,606 19.1K +9% —
D 2021-10-01 2021-09-30 MNPR Mazar Andrew Paul CSO, Dir M - OptEx $0.00 -1,606 20.9K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-09-30 F D 471 $4.87 18,673.80 D — —
2 Common Common Stock 2021-09-30 M A 1,606 — 19,144.80 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
3 Derivative Restricted Stock Units 2021-09-30 M D 1,606 $0.00 20,879 D — · — to — 1,606 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 26, 2021, the reporting person was granted 25,697 restricted stock units, vesting 6/48ths (3,212 shares) on June 30, 2021, and 3/48ths (1,606 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.